Anicet Okinga is the new Pharmaceutical Patent Senior Advisor at Licks Attorneys

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Anicet Okinga is the new Pharmaceutical Patent Senior Advisor at Licks Attorneys

Sponsored by

Licks_Brazil.png

Licks Attorneys announce Anicet Okinga as the new Pharmaceutical Patent Senior Advisor at Licks Attorneys

Licks Attorneys is pleased to announce the hiring of Prof. Dr. Anicet Okinga, DDS Oral and Dental Surgeon, PharmD, Doctor in Pharmaceutical Sciences, as the firm’s new Pharmaceutical Patents Senior Advisor. His arrival reinforces the firm’s strategic focus on scientific excellence, high complexity patent matters, and technical depth in the pharmaceutical sector.

Prof. Dr. Okinga brings a multidisciplinary background that spans dentistry, pharmacy, and advanced research in clinical and experimental pathophysiology. His scientific experience includes work in pharmacology, neuroscience, inflammation, metabolism, and bioactive compounds—knowledge that strengthens the firm’s ability to support clients in highly technical patent disputes and prosecution strategies.

From 2017 to 2026, he served as a Patent Examiner in the Pharmaceuticals Art Unit at the Brazilian Patent and Trademark Office (BRPTO), where he conducted substantive examination of applications involving pharmaceutical compounds, formulations, delivery systems, and medical uses. His perspective as a former examiner adds a valuable regulatory and procedural dimension to the team’s work, supporting informed and effective strategies for innovation driven clients.

His training includes the Cycle Long “Brevets d’invention” at the Université de Strasbourg (UNISTRA) and advanced programs from WIPO, the EPO, and the European Patent Academy, with focus on patent drafting, examination procedures, unity of invention, and European patent law.

Beyond his technical background, Prof. Dr. Okinga has contributed to governance and diversity initiatives, serving as Honorary Counselor at the State Council for the Rights of Black People and the Promotion of Racial Equality in Rio de Janeiro (CEDINE RJ) and collaborating with the Racial Equality Commission of the Brazilian Bar Association (OAB/RJ). He also chaired the BRPTO Careers and Positions Commission between 2021 and 2023 and holds a LideraGov 4.0 certification for innovation oriented public leadership.

Anicet Okinga arrival strengthens Licks Attorneys’ capacity to navigate the intersection of science, regulation, and intellectual property, offering clients a deeper technical foundation in pharmaceutical innovation and patent protection.

more from across site and SHARED ros bottom lb

More from across our site

Rebekah Gay discusses overcoming self-doubt, supporting the next generation of women lawyers, and how changing client demands are reshaping IP practice
New filing data suggests Germany's grip on UPC litigation remains strong, while Bardehle Pagenberg, Arnold Ruess, Hogan Lovells and Carpmaels notch up notable cases
In 27 years, KASS has expanded to seven countries in southeast Asia and is now eyeing further growth opportunities. Its CEO shares her perspective
Mine Güner discusses bridging law and business, taking the initiative, and why Taylor Swift helped put copyright on the map
Cindy Goh discusses why she launched Cheang & Ariff's IP department, the improving litigation environment in Malaysia and what to consider when using AI
Increased focus on adding patent litigation depth to the firm’s Dallas office was behind the boutique’s most recent hires
IPH's Canadian acquisitions are paying off on paper, but a couple of strong years may not be enough to show that the group's strategy has truly won over the market
Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators
Firms with established sports relationships and specialised expertise are well positioned to capture the market’s expanded pool of IP work
Gift this article